Transdermal Delivery of Insulin from a Novel Biphasic Lipid System in Diabetic Rats

Abstract

Noninvasive transdermal insulin delivery could provide diabetic patients with sustained physiological levels of basal insulin in a pain-free manner. We have developed a novel transdermal lipid-based system(Biphasix™) suitable for macromolecule delivery across the skin. The objective of this study was to evaluate the pharmacological effects of the Biphasix-insulin delivery system in a diabetic rat model. Transdermal patches (one per animal) containing Biphasix-insulin formulation (10 mg of recombinant human insulin dose) were applied to the shaved abdominal skin of streptozotocin-induced diabetic rats for 48 h. Blood glucose was monitored every 2-4 h using a Lifescan glucose meter. Serum insulin levels were analysed by enzyme-linked immunosorbent assay. A decrease in blood glucose of 43.7 ± 3.8% (mean± SEM, n = 25) was observed compared with initial blood glucose levels. The duration of the response was 51.5 ± 3.7 h (mean ± SEM, n = 25). Serum insulin after application of the transdermal Biphasix-insulin patch was 20.08 ± 5.44 μIU/mL (mean ± SEM, n = 13) during the steady state, which was not statistically different from the insulin levels obtained 2 h after subcutaneous injection of 1 mg of recombinant human insulin solution. Insulin bioavailability from the transdermal Biphasix-insulin patches was 21.5 ± 6.9% (mean ± SEM,n = 13) based on serum insulin and 39.5 ± 8.5% (mean ± SEM, n = 25) based on the pharmacodynamic blood glucose-lowering effects. The Biphasix system successfully delivered insulin transdermally, as evidenced by a significant sustained decrease in blood glucose in diabetic rats, with a corresponding increase in serum insulin. These results support the feasibility of developing a transdermal insulin patch for human applications.